​
​

Allogene Therapeutics (ALLO) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Allogene Therapeutics Revenue Highlights

Latest Revenue (Y)

$95.00K

0

Allogene Therapeutics Revenue by Period

Allogene Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$95.00K-60.91%
2022-12-31$243.00K-99.37%
2021-12-31$38.49M100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31--

Allogene Therapeutics generated $95.00K in revenue during NA 2023, up -60.91% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Allogene Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30-100.00%
2024-06-30--100.00%
2024-03-31$22.00K4.76%
2023-12-31$21.00K-51.16%
2023-09-30$43.00K-2.27%
2023-06-30$44.00K-15.38%
2023-03-31$52.00K10.64%
2022-12-31$47.00K-4.08%
2022-09-30$49.00K-43.02%
2022-06-30$86.00K40.98%
2022-03-31$61.00K19.61%
2021-12-31$51.00K4.08%
2021-09-30$49.00K11.36%
2021-06-30$44.00K-99.89%
2021-03-31$38.34M100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31--

Allogene Therapeutics generated - in revenue during Q3 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Allogene Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
BEAMBeam Therapeutics$377.71M$14.27M
BPMCBlueprint Medicines$249.38M$128.18M
SGMOSangamo Therapeutics$176.23M$356.00K
HRTXHeron Therapeutics$127.04M$36.02M
GTHXG1 Therapeutics$82.51M$16.55M
NTLAIntellia Therapeutics$36.27M$9.11M
CRBUCaribou Biosciences$34.48M$3.46M
VECTVectivBio$27.34M$676.00K
RLAYRelay Therapeutics$25.55M-
ITOSiTeos Therapeutics$12.60M$35.00M
VERVVerve Therapeutics$11.76M$6.87M
IPSCCentury Therapeutics$2.23M$791.00K
LIFEaTyr Pharma$353.00K$235.00K
ALLOAllogene Therapeutics$95.00K-
EDITEditas Medicine--
PRMEPrime Medicine-$39.31M
ANNXAnnexon--
SANASana Bio--

ALLO Revenue FAQ

What is Allogene Therapeutics’s yearly revenue?

Allogene Therapeutics's yearly revenue for 2023 was $95K, representing a decrease of -60.91% compared to 2022. The company's yearly revenue for 2022 was $243K, representing a decrease of -99.37% compared to 2021. ALLO's yearly revenue for 2021 was $38.49M, representing an increase of 100.00% compared to 2020.

What is Allogene Therapeutics’s quarterly revenue?

Allogene Therapeutics's quarterly revenue for Q3 2024 was $0, a 100.00% increase from the previous quarter (Q2 2024), and a -100.00% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). ALLO's quarterly revenue for Q1 2024 was $22K, a 4.76% increase from the previous quarter (Q4 2023), and a -57.69% decrease year-over-year (Q1 2023).

What is Allogene Therapeutics’s revenue growth rate?

Allogene Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -99.75%, and for the last 5 years (2019-2023) was 0%.